Cargando…
Modeling the competition between lung metastases and the immune system using agents
BACKGROUND: The Triplex cell vaccine is a cancer cellular vaccine that can prevent almost completely the mammary tumor onset in HER-2/neu transgenic mice. In a translational perspective, the activity of the Triplex vaccine was also investigated against lung metastases showing that the vaccine is an...
Autores principales: | , , , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2957681/ https://www.ncbi.nlm.nih.gov/pubmed/21106120 http://dx.doi.org/10.1186/1471-2105-11-S7-S13 |
_version_ | 1782188248223711232 |
---|---|
author | Pennisi, Marzio Pappalardo, Francesco Palladini, Ariannna Nicoletti, Giordano Nanni, Patrizia Lollini, Pier-Luigi Motta, Santo |
author_facet | Pennisi, Marzio Pappalardo, Francesco Palladini, Ariannna Nicoletti, Giordano Nanni, Patrizia Lollini, Pier-Luigi Motta, Santo |
author_sort | Pennisi, Marzio |
collection | PubMed |
description | BACKGROUND: The Triplex cell vaccine is a cancer cellular vaccine that can prevent almost completely the mammary tumor onset in HER-2/neu transgenic mice. In a translational perspective, the activity of the Triplex vaccine was also investigated against lung metastases showing that the vaccine is an effective treatment also for the cure of metastases. A future human application of the Triplex vaccine should take into account several aspects of biological behavior of the involved entities to improve the efficacy of therapeutic treatment and to try to predict, for example, the outcomes of longer experiments in order to move faster towards clinical phase I trials. To help to address this problem, MetastaSim, a hybrid Agent Based - ODE model for the simulation of the vaccine-elicited immune system response against lung metastases in mice is presented. The model is used as in silico wet-lab. As a first application MetastaSim is used to find protocols capable of maximizing the total number of prevented metastases, minimizing the number of vaccine administrations. RESULTS: The model shows that it is possible to obtain "in silico" a 45% reduction in the number of vaccinations. The analysis of the results further suggests that any optimal protocol for preventing lung metastases formation should be composed by an initial massive vaccine dosage followed by few vaccine recalls. CONCLUSIONS: Such a reduction may represent an important result from the point of view of translational medicine to humans, since a downsizing of the number of vaccinations is usually advisable in order to minimize undesirable effects. The suggested vaccination strategy also represents a notable outcome. Even if this strategy is commonly used for many infectious diseases such as tetanus and hepatitis-B, it can be in fact considered as a relevant result in the field of cancer-vaccines immunotherapy. These results can be then used and verified in future "in vivo" experiments, and their outcome can be used to further improve and refine the model. |
format | Text |
id | pubmed-2957681 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2010 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-29576812010-10-21 Modeling the competition between lung metastases and the immune system using agents Pennisi, Marzio Pappalardo, Francesco Palladini, Ariannna Nicoletti, Giordano Nanni, Patrizia Lollini, Pier-Luigi Motta, Santo BMC Bioinformatics Proceedings BACKGROUND: The Triplex cell vaccine is a cancer cellular vaccine that can prevent almost completely the mammary tumor onset in HER-2/neu transgenic mice. In a translational perspective, the activity of the Triplex vaccine was also investigated against lung metastases showing that the vaccine is an effective treatment also for the cure of metastases. A future human application of the Triplex vaccine should take into account several aspects of biological behavior of the involved entities to improve the efficacy of therapeutic treatment and to try to predict, for example, the outcomes of longer experiments in order to move faster towards clinical phase I trials. To help to address this problem, MetastaSim, a hybrid Agent Based - ODE model for the simulation of the vaccine-elicited immune system response against lung metastases in mice is presented. The model is used as in silico wet-lab. As a first application MetastaSim is used to find protocols capable of maximizing the total number of prevented metastases, minimizing the number of vaccine administrations. RESULTS: The model shows that it is possible to obtain "in silico" a 45% reduction in the number of vaccinations. The analysis of the results further suggests that any optimal protocol for preventing lung metastases formation should be composed by an initial massive vaccine dosage followed by few vaccine recalls. CONCLUSIONS: Such a reduction may represent an important result from the point of view of translational medicine to humans, since a downsizing of the number of vaccinations is usually advisable in order to minimize undesirable effects. The suggested vaccination strategy also represents a notable outcome. Even if this strategy is commonly used for many infectious diseases such as tetanus and hepatitis-B, it can be in fact considered as a relevant result in the field of cancer-vaccines immunotherapy. These results can be then used and verified in future "in vivo" experiments, and their outcome can be used to further improve and refine the model. BioMed Central 2010-10-15 /pmc/articles/PMC2957681/ /pubmed/21106120 http://dx.doi.org/10.1186/1471-2105-11-S7-S13 Text en Copyright ©2010 Pennisi et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Proceedings Pennisi, Marzio Pappalardo, Francesco Palladini, Ariannna Nicoletti, Giordano Nanni, Patrizia Lollini, Pier-Luigi Motta, Santo Modeling the competition between lung metastases and the immune system using agents |
title | Modeling the competition between lung metastases and the immune system using agents |
title_full | Modeling the competition between lung metastases and the immune system using agents |
title_fullStr | Modeling the competition between lung metastases and the immune system using agents |
title_full_unstemmed | Modeling the competition between lung metastases and the immune system using agents |
title_short | Modeling the competition between lung metastases and the immune system using agents |
title_sort | modeling the competition between lung metastases and the immune system using agents |
topic | Proceedings |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2957681/ https://www.ncbi.nlm.nih.gov/pubmed/21106120 http://dx.doi.org/10.1186/1471-2105-11-S7-S13 |
work_keys_str_mv | AT pennisimarzio modelingthecompetitionbetweenlungmetastasesandtheimmunesystemusingagents AT pappalardofrancesco modelingthecompetitionbetweenlungmetastasesandtheimmunesystemusingagents AT palladiniariannna modelingthecompetitionbetweenlungmetastasesandtheimmunesystemusingagents AT nicolettigiordano modelingthecompetitionbetweenlungmetastasesandtheimmunesystemusingagents AT nannipatrizia modelingthecompetitionbetweenlungmetastasesandtheimmunesystemusingagents AT lollinipierluigi modelingthecompetitionbetweenlungmetastasesandtheimmunesystemusingagents AT mottasanto modelingthecompetitionbetweenlungmetastasesandtheimmunesystemusingagents |